AVITA Downgraded by Piper Sandler Over Sales Outlook
AVITA Medical Analyst Ratings
Piper Sandler Reaffirms Their Hold Rating on Avita Medical (RCEL)
Steady Performance and Promising Outlook: A Buy Rating for Avita Medical
Piper Sandler Downgrades Avita Medical to Neutral From Overweight, Price Target Is $9
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL) and CVRx (CVRX)
Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target Is AU$3.03
Lake Street Keeps Their Buy Rating on Avita Medical (RCEL)
AVITA Medical Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)
TD Cowen Keeps Their Buy Rating on Avita Medical (RCEL)
AVITA Medical Analyst Ratings
Piper Sandler Sticks to Its Buy Rating for Avita Medical (RCEL)
Avita Medical Poised for Growth: Strong Q4 Performance and Promising 2024 Outlook Reinforce Buy Rating
Buy Rating Affirmed for Avita Medical on Strong Financials and Expansive Growth Strategy
Avita Medical (RCEL) Receives a Buy From Lake Street
AVITA Medical Analyst Ratings
Avita Medical (RCEL) Gets a Buy From BTIG
BTIG Sticks to Its Buy Rating for Avita Medical (RCEL)
What 4 Analyst Ratings Have To Say About AVITA Medical
No Data